Product Details
| Alternative Name: | PI9, Serpin B9, CAP3, Cytoplasmic antiproteinase 3 |
| |
| Clone: | PI9-17 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Recombinant human full-length PI9 (proteinase inhibitor 9). |
| |
| UniProt ID: | P50453 |
| |
| Species reactivity: | Human
|
| |
| Crossreactivity: | Does not cross-react with PI6, PI8 or PAI-2. |
| |
| Applications: | IHC (PS), WB
|
| |
| Recommended Dilutions/Conditions: | Immunohistochemistry (formaldehyde-fixed paraffin-embedded human tissues after pretreatment with 10mM citric acid pH 6.0 for 20min; use ~1:100. For fixed cytospin preparations fix cells for 10min in 10% formalin and then treat them as paraffin sections)
Western Blot (standard procedures)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects bands of ~42kDa (native PI9) and ~67kDa (PI9 complexed to granzyme B) by Western blot.
Not suitable for Flow Cytometry. |
| |
| Positive Control: | YT-Indy cells (a natural killer leukemia cell line) can be used as positive control. In other cell lines a non-specific protein band of ~63kDa can be detected. |
| |
| Formulation: | Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | The human intracellular serpin proteinase inhibitor 9 (PI9) is the only human protein able to inhibit the activity of the serine protease granzyme B. Granzyme B is expressed by cytotoxic lymphocytes and induces rapid target cell apoptosis. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Figure 1: Tissue sections of T-ALCL a) stained with MAb to PI9 (Prod. No.
ALX-804-457) and b) double-stained with MAb to PI9 (red) (Prod. No.
ALX-804-457) and granzyme B (brown). In panel b the arrows point to tumor-infiltrating CTLs positive for granzyme B and the arrowhead denotes an example of a PI9
+ neoplastic cell."
Figure 2: The following tumors were stained for PI9: a) B-CLL and b) classical Hodgkin disease, nodular sclerosing subtype.
Please mouse over
Product Literature References
Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis: J.A. Kummer, et al.; Cell Death Differ.
14, 1486 (2007),
Abstract;
Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma: I.S. van Houdt, et al.; Clin. Cancer Res.
11, 6400 (2005),
Abstract;
Full Text
High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis: S.A. Riemersma, et al.; J. Pathol.
206, 328 (2005),
Abstract;
Full Text
Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection: A.T. Rowshani, et al.; Kidney Int.
66, 1417 (2004),
Abstract;
Full Text
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?: B.A. Bladergroen, et al.; Blood
99, 232 (2002),
Abstract;
Full Text
Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9: P. Kannan-Thulasiraman & D.J. Shapiro; J. Biol. Chem.
277, 41230 (2002),
Abstract;
Full Text
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites: B.A. Bladergroen, et al.; J. Immunol.
166, 3218 (2001),
Abstract;
Full Text
General Literature References
Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9: R.R. Annand, et al.; Biochem. J.
342 Pt 3, 655 (1999),
Abstract;
Full Text
Inhibition of neutrophil elastase by recombinant human proteinase inhibitor 9: J.R. Dahlen, et al.; Biochim. Biophys. Acta
1451, 233 (1999),
Abstract;
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway: C.H. Bird, et al.; Mol. Cell. Biol.
18, 6387 (1998),
Abstract;
Human proteinase inhibitor 9 (PI9) is a potent inhibitor of subtilisin A: J.R. Dahlen, et al.; BBRC
238, 329 (1997),
Abstract;
